International Journal of Medical Science Research and Development (ISCSITR-IJMSRD)

Vol.5, Iss. 2, Jul-Dec, 2024, pp. 1-9.

https://iscsitr.com/index.php/ISCSITR-IJMSRD

Journal ID: 9125-8813

CRISPR-Cas9 Mediated Epigenetic Reprogramming of Cardiac Fibroblasts as a Therapeutic Strategy for Post-Infarction Myocardial Remodeling

Giuseppe Antonio,

Pharmaceutical Scientist,

Italy.

Abstract

Myocardial infarction (MI) triggers extensive fibrosis, driven largely by cardiac fibroblasts (CFs), which compromises cardiac function. Traditional therapies fail to reverse fibrotic remodeling, making regenerative strategies imperative. In recent years, CRISPR-Cas9-based gene editing has emerged as a precision tool for reprogramming somatic cells. By epigenetically reprogramming CFs into induced cardiomyocyte-like cells (iCMs), researchers aim to repair infarcted myocardium. This paper explores the potential of CRISPR-mediated transcriptional modulation to reverse fibrotic phenotypes and initiate regenerative pathways. We contextualize findings, outline a proposed therapeutic pipeline, and review barriers such as delivery, off-target effects, and chromatin accessibility.

Keywords: CRISPR-Cas9, epigenetic reprogramming, cardiac fibroblasts, myocardial infarction, regenerative medicine, fibrosis reversal, iCMs

How to cite this paper: Giuseppe Antonio. (2024) CRISPR-Cas9 Mediated Epigenetic Reprogramming of Cardiac Fibroblasts as a Therapeutic Strategy for Post-Infarction Myocardial Remodeling. *International Journal of Medical Science Research and Development (ISCSITR-IJMSRD)*, 5(2). 1-9.

URL: https://iscsitr.com/index.php/ISCSITR-IJMSRD/article/view/ISCSITR-IJMSRD_05_02_001

Published: 20th Feb 2024

1. INTRODUCTION

Post-infarction myocardial remodeling is a leading cause of heart failure worldwide. Following ischemic injury, cardiac fibroblasts, which comprise 60–70% of the total cell population in the heart, become activated and differentiate into myofibroblasts, secreting extracellular matrix components that exacerbate fibrotic scarring. This process, though initially reparative, becomes maladaptive over time, limiting cardiac contractility and function.

Advancements in genome editing, particularly the CRISPR-Cas9 system, have opened new avenues for cardiac regeneration. Unlike traditional gene therapy, CRISPR-Cas9 offers locus-specific targeting and the potential to modulate endogenous gene networks epigenetically. The catalytically dead Cas9 (dCas9) fused with transcriptional effectors (e.g., KRAB or VP64) can selectively repress or activate cardiac-specific genes without creating double-strand breaks, reducing genotoxic risks. This paper synthesizes current knowledge up to 2021 and proposes a novel therapeutic strategy that integrates CRISPR-mediated epigenetic modulation for direct cardiac reprogramming.

2. Literature Review

The field of cardiac reprogramming has advanced significantly over the past decade. Ieda et al. (2010) demonstrated that transcription factors Gata4, Mef2c, and Tbx5 (GMT) could reprogram fibroblasts into iCMs. However, low efficiency and incomplete reprogramming limited translational potential. Jayawardena et al. (2012) reported enhanced reprogramming via microRNA delivery, suggesting a role for epigenetic modulation. Marotta et al. (2018) emphasized the necessity to overcome chromatin barriers during reprogramming, while Wang et al. (2020) introduced dCas9-VP64 systems to activate endogenous cardiac genes, showing higher stability than viral GMT delivery.

Emerging studies explored the repression of fibroblast identity as a complementary strategy. For example, Tang et al. (2021) targeted EZH2 to remove H3K27me3 marks, enhancing cardiac gene activation. Yu et al. (2019) performed genome-wide CRISPR-KO screens, identifying Dmap1 as a key reprogramming regulator. Similarly, Cho et al. (2021) highlighted the benefits of combining CRISPR activation with small-molecule epigenetic

modulators.

Despite these insights, challenges persist. Delivery vectors for in vivo cardiac application remain limited, off-target editing risks demand resolution, and cell-type-specific targeting remains underdeveloped. Most importantly, studies underscore that full cardiomyocyte phenotype induction requires both activation of cardiogenic pathways and suppression of profibrotic networks.

3. Proposed Architecture for Therapeutic Strategy

3.1 Molecular Strategy

The molecular strategy underpinning CRISPR-Cas9-mediated cardiac fibroblast reprogramming hinges on precise transcriptional modulation of gene networks involved in cardiogenesis and fibrosis. Utilizing a catalytically dead Cas9 (dCas9) fused to VP64 (a transcriptional activator), the system can upregulate critical cardiac transcription factors such as *Nkx2.5*, *Gata4*, *Mef2c*, and *Tbx5*. These genes are known to initiate and stabilize cardiomyocyte-like phenotypes in fibroblasts. Parallelly, repression of fibrotic genes like *Postn* (periostin) and *Col1a1* (collagen type I alpha 1 chain) via dCas9-KRAB ensures suppression of myofibroblast activity, halting extracellular matrix deposition that exacerbates scarring post-infarction.

For in vivo applications, effective delivery remains a pivotal challenge. Among leading vectors, adeno-associated virus serotype 9 (AAV9) demonstrates strong cardiac tropism and low immunogenicity, making it ideal for targeted myocardial gene delivery. Alternatively, lipid nanoparticles (LNPs) are emerging as non-viral delivery systems that can be engineered for cardiac fibroblast specificity through surface ligand modifications. Both vectors support the stable expression of dCas9-based constructs, enabling spatially and temporally controlled reprogramming with reduced systemic toxicity.

3.2 Workflow Steps

The therapeutic workflow begins with **injury detection**, where a myocardial infarction (MI) is diagnosed using clinical imaging and biomarkers such as troponin. This identification is critical for timely intervention before fibrotic remodeling advances irreversibly. Upon confirmation, **vector administration** follows, typically via direct intramyocardial injection

or catheter-based delivery systems. These vectors, either viral (e.g., AAV9) or non-viral (e.g., lipid nanoparticles), are engineered to specifically target cardiac fibroblasts and deliver dCas9 fusion constructs.

Once internalized by the fibroblasts, **CRISPR activation** is initiated through dCas9-VP64 or dCas9-KRAB systems, enabling transcriptional control of key genes—upregulating cardiac transcription factors and silencing fibrotic markers. This leads to **phenotypic conversion** of fibroblasts into induced cardiomyocyte-like cells (iCMs), which gradually integrate into native myocardium. Over time, **tissue regeneration** occurs as iCMs contribute to contractile function, potentially reversing pathological remodeling and restoring cardiac output, marking a paradigm shift in post-MI regenerative therapy.



Figure 1: CRISPR-Cas9 Mediated Epigenetic Reprogramming for Cardiac Repair Post-Myocardial Infarction

4. Integrated Framework of CRISPR-Based Cardiac Reprogramming

CRISPR-based cardiac repair relies on a convergence of multiple biological, technological, and clinical elements. At its core, the approach utilizes programmable epigenetic tools like dCas9-VP64 for gene activation and dCas9-KRAB for repression,

allowing precise transcriptional control without altering the underlying DNA sequence. These tools target cardiogenic genes such as *Nkx2.5*, *Gata4*, *Tbx5*, and *Mef2c*, which are essential for initiating and maintaining cardiac cell identity. Concurrently, fibroblast-associated genes like *Postn* and *Col1a1* are suppressed to dismantle the fibrotic phenotype and prevent adverse remodeling. These dual gene targets illustrate how reprogramming hinges on both positive induction of lineage-specific pathways and silencing of lineage-inappropriate ones.

In addition to molecular targets, the success of this strategy depends heavily on effective delivery modalities. Adeno-associated virus serotype 9 (AAV9) and lipid nanoparticles (LNPs) are among the most promising vectors due to their cardiac tropism and tunable specificity. These systems are engineered to deliver CRISPR constructs selectively to cardiac fibroblasts post-infarction. Clinically, this multi-faceted reprogramming model aims to mitigate myocardial fibrosis, regenerate lost cardiomyocytes, and ultimately restore cardiac function. The integration of molecular biology with delivery engineering and regenerative medicine forms the conceptual backbone of the CRISPR-based approach to treating myocardial infarction.

4.1 Stepwise Mechanism of CRISPR-Guided Cellular Reprogramming

The process of CRISPR-mediated epigenetic reprogramming of cardiac fibroblasts unfolds through a defined and biologically synchronized sequence. It begins with the detection of myocardial infarction (MI) through clinical diagnostics such as ECG, cardiac biomarkers, and imaging. Upon identification, CRISPR delivery is initiated, commonly via intramyocardial injection or catheter-guided vector administration. The therapeutic vector—carrying the dCas9-based construct—is engineered for selective uptake by cardiac fibroblasts within the infarct zone. Once inside the target cells, the construct binds to predefined genomic loci to either activate cardiac-specific transcription factors or repress fibroblast-specific genes.

This gene modulation phase marks the transition into reprogramming, where fibroblasts gradually acquire features of induced cardiomyocytes (iCMs), including altered gene expression, morphology, and contractile protein synthesis. Over time, these iCMs begin integrating functionally and structurally into the damaged myocardium, contributing to

tissue repair and improved cardiac output. The process, though conceptually straightforward, demands precise timing, vector optimization, and sustained transcriptional control to ensure durable and safe cellular conversion. This stepwise process underscores the transformative ability of CRISPR systems to reprogram cellular identity and promote heart tissue regeneration directly within the damaged myocardium.

4.2 Infographic on Epigenetic Barriers

Epigenetic barriers are critical determinants of reprogramming efficiency and fidelity in cardiac fibroblasts. These barriers primarily include DNA methylation, histone modifications, and chromatin remodeling—mechanisms that collectively maintain fibroblast identity and restrict the activation of cardiomyocyte-specific genes. In cardiac fibroblasts, key promoters for cardiac transcription factors (*Nkx2.5*, *Gata4*, *Tbx5*) are often marked by repressive histone marks like H3K27me3 or are heavily methylated at CpG islands, preventing transcription factor binding. Additionally, tightly packed chromatin configurations (heterochromatin) limit access to gene regulatory elements, making transcriptional activation via CRISPR-dCas9 or other tools less efficient.

To overcome these barriers, targeted epigenetic modulation is essential. The infographic visually demonstrates these mechanisms: a cardiac fibroblast with compacted chromatin is depicted on the left, while the right side illustrates the layered structure of chromatin—highlighting methylation marks and histone tail modifications (e.g., acetylation, methylation). The involvement of chromatin remodeling enzymes such as EZH2 (a histone methyltransferase), HDACs (histone deacetylases), and DNMTs (DNA methyltransferases) is also illustrated, as these enzymes reinforce repressive chromatin states. In CRISPR-aided reprogramming, these epigenetic features act as barriers to transcriptional initiation, but their inhibition—either by dCas9-repressor constructs or pharmacological agents—can help unlock lineage-specific gene expression, thereby enabling effective conversion of fibroblasts into cardiomyocyte-like cells.



Figure 2: Overcoming Epigenetic Barriers in Cardiac Fibroblast Reprogramming

5. Synergistic Potential of CRISPR with Small Molecule Epigenetic Modulators

The integration of CRISPR-based transcriptional modulation with small molecule epigenetic drugs presents a promising hybrid strategy to enhance cardiac fibroblast reprogramming. While CRISPR-dCas9 systems provide gene-specific activation or repression, their efficacy is often constrained by chromatin accessibility. Small molecules such as histone deacetylase inhibitors (e.g., valproic acid), DNA methyltransferase inhibitors (e.g., 5-azacytidine), or EZH2 inhibitors can relax repressive chromatin architecture, thereby increasing the binding efficiency of dCas9 effectors to target loci. This dual-pronged approach could enable both activation of dormant cardiac genes and suppression of fibrotic programs in a more robust and sustained manner than CRISPR alone.

Furthermore, such combinatorial therapies may allow transient and tunable control of reprogramming kinetics, reducing long-term risks associated with permanent genetic modifications. For instance, small molecules can be systemically administered and withdrawn as needed, offering a safety advantage. Recent preclinical studies have demonstrated that cardiac reprogramming efficiency can be nearly doubled when CRISPR transcriptional activators are applied in tandem with chromatin-modifying agents. This synergy suggests a future where tailored cocktails of CRISPR constructs and pharmacologic

modulators are delivered in sequence or co-encapsulated in delivery vehicles, pushing the boundaries of regenerative cardiology.

6. Challenges and Future Directions

Despite the growing promise of CRISPR-Cas9 in regenerative cardiology, several **technical and biological challenges** must be addressed before clinical translation. One major hurdle is **efficient and targeted delivery** of gene-editing tools specifically to cardiac fibroblasts without affecting other myocardial or systemic cell types. Current delivery systems like AAV9 have cardiac tropism but can still result in off-target effects, immunogenicity, and limited packaging capacity. Additionally, **lipid nanoparticles**, while tunable and non-immunogenic, often suffer from low transfection efficiency in fibrotic tissues.

Equally pressing is the concern of **epigenetic memory and incomplete reprogramming**. Fibroblasts retain lineage-specific transcriptional signatures and chromatin marks, making full transdifferentiation into functional cardiomyocytes difficult. While CRISPR activators can initiate cardiogenic programs, sustained expression and proper chromatin remodeling are essential to stabilize the iCM phenotype. To this end, **combinatorial approaches**—using small-molecule chromatin modifiers, enhancer-targeting CRISPR systems, or 3D cardiac tissue scaffolds—are under active investigation. Furthermore, **long-term safety** remains uncertain; although dCas9 is nuclease-deficient, off-target binding and transcriptional dysregulation may still occur, underscoring the need for high-fidelity dCas9 variants and inducible expression systems.

References

[1] Basu, A., and Tiwari, V. K. "Epigenetic reprogramming of cell identity: lessons from development for regenerative medicine." *Clinical Epigenetics*, 2021.

[2] Wang, J., et al. "Lineage reprogramming of fibroblasts into induced cardiac progenitor cells by CRISPR/Cas9-based transcriptional activators." *Acta Pharmaceutica Sinica B*, 2020.

[3] Tang, Y., et al. "Inhibition of EZH2 primes cardiac gene activation via removal of epigenetic repression." *Stem Cell Research & Therapy*, 2021.

[4] Yu, J. S. L., et al. "CRISPR-knockout screen identifies Dmap1 as a regulator of cardiac progenitor reprogramming." *Stem Cells*, 2019.

[5] Adams, E., et al. "Direct reprogramming of cardiac fibroblasts to repair the injured heart." *Journal of Cardiovascular Development and Disease*, 2021.

[6] Cho, H. M., and Cho, J. Y. "Genome-edited stem cell therapy for ischemic heart disease." *Stem Cell Reviews and Reports*, 2021.

[7] Jayawardena, T. M., et al. "MicroRNA-mediated direct reprogramming of cardiac fibroblasts to cardiomyocytes." *Circulation Research*, 2012.

[8] Marotta, P., et al. "Combining cell and gene therapy to advance cardiac regeneration." *Expert Opinion on Biological Therapy*, 2018.

[9] Burridge, P. W., et al. "Genetic and epigenetic regulation of human cardiac reprogramming." *Annual Review of Genetics*, 2015.

[10] Breuls, N., et al. "(Epi) genetic modifications in myogenic stem cells." *Cells*, 2019.

[11] Mohamed, T. M. A., et al. "Chemical enhancement of direct cardiac reprogramming." *Circulation*, 2017.

[12] Huang, W., et al. "Strategies to improve cellular programming-based approaches for heart regeneration." *International Journal of Molecular Sciences*, 2020.

[13] Riching, A. S., and Song, K. "Cardiac regeneration: new insights." *Frontiers in Bioengineering and Biotechnology*, 2021.

[14] Grath, A., and Dai, G. "Direct cell reprogramming for regenerative medicine." *Journal of Biological Engineering*, 2019.

[15] Wang, Q., et al. "Direct in vivo reprogramming with nanoparticles for cardiac regeneration." *Biomaterials*, 2021.